Clinical Trials
Eradivir's mission is to tackle the world's most prevalent diseases.
Clinical trials are the gold standard by which we measure the safety and efficacy of our therapeutics. Safety and compliance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH GCP) guidelines are at the forefront of our clinical trial designs and scientific considerations.
Before we consider dosing our first patient, we design and run innovative pre-clinical studies to answer critical questions about safety, tolerability, dosing regimen, pharmacokinetics, pharmacodynamics, biomarkers, and efficacy to inform the minimal exposure of our drug necessary to treat critical infections and diseases.
We are eternally thankful for the volunteers and patients who participate in our trials.
As part of our commitment to transparency within the scientific and patient community, Eradivir posts regular updates to regulatory authority websites on the progress of our clinical trials.
Updates can be found at:
EUClinicalTrials.euClinicalTrials.govas applicable by searching for the clinical trial numbers below.
Indication | Program | Name | Trial Number |
---|---|---|---|
Influenza | EV25 | Phase 1 | EUCT#: 2024-514832-26-SAD |
Influenza | EV25 | Phase 2a | EUCT#: 2024-514832-26-CHIM |
Influenza | EV25 | Phase 2b | EV-FLU-CL-02 |